Drug

LY03003

As of the edition of 20 October 2026, LY03003 is a drug known only by a code name: in active development; acts on DRD2, DRD3 and DRD4.

Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.

The drug

Status
Active, 2018
Kind
Code name only
Registered trials
8, 0 stopped early
Disease areas
Nervous system

US protection

No US approval on record.

With no US approval on record there are no listed US patents or exclusivities.

This is the US only.

Targets

GeneProteinUniProt
DRD2Dopamine receptor D2P14416
DRD4Dopamine receptor D4P21917
DRD3Dopamine receptor D3P35462

Registered trials

PhaseTrialsCompletedActiveStopped early
Phase 16600
Phase 32200
All trials8

Who ran its trials

CompanyRoleYears
Luye PharmaLead sponsor of trials2013 to now